Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Transcutaneous carbon dioxide profile during sleep reveals metabolic risk factors in post-menopausal females

J. Aittokallio, T. Saaresranta, A. Virkki, N. Karppinen, O. J. Heinonen, T. Aittokallio, O. Polo
European Respiratory Journal 2009 34: 1132-1139; DOI: 10.1183/09031936.00017909
J. Aittokallio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Saaresranta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Virkki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Karppinen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. J. Heinonen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Aittokallio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Polo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The risks of metabolic syndrome and sleep-disordered breathing increase around the time of the menopause. We have previously shown that features of the nocturnal transcutaneous carbon dioxide (TcCO2) profile are associated with metabolic variables such as cholesterol, glycosylated haemoglobin A1C (GHbA1C) and blood pressure in patients with sleep apnoea. In the present study, we investigated whether these metabolic variables can be predicted using noninvasive TcCO2 measurements during sleep in generally healthy post-menopausal females.

22 post-menopausal females underwent an overnight polygraphic sleep study that involved the continuous monitoring of arterial oxygen saturation (Sa,O2) and TcCO2. Body composition, GHbA1C, plasma cholesterol and blood pressure were measured prior to the sleep study.

Nocturnal TcCO2 features were the most important predictors of lipoprotein cholesterols, triglycerides and blood pressure levels. A longer sleep period and higher TcCO2 levels were linked with lower GHbA1C, and fragmented sleep with lower high-density lipoprotein cholesterol. Neither nocturnal Sa,O2 indices nor the apnoea/hypopnoea index had a predictive power.

The results suggest that nocturnal TcCO2 events revealed metabolic risk factors already present in healthy post-menopausal females.

  • Metabolic syndrome
  • post menopause
  • sleep
  • transcutaneous carbon dioxide

There is increasing evidence to suggest that sleep disorders and cardiovascular diseases are linked. Aging and menopause increase the risk of sleep-disordered breathing (SDB) and poor sleep quality, and each of these are also associated with metabolic disorders 1–3. Although the mechanisms of interaction between sleep disorders and cardiovascular diseases are not fully understood, an autonomic nervous system imbalance (increased sympathetic and decreased parasympathetic activity) and endothelial inflammation are likely to be involved.

The transcutaneous carbon dioxide (TcCO2) sensor has been developed for noninvasive estimation of the partial pressure of arterial carbon dioxide. The method has not gained wide acceptance because the correlations between TcCO2 and arterial carbon dioxide tension are affected by haemodynamic events, such as vasoconstriction and vasodilatation 4, 5. However, measurement of local carbon dioxide is of special interest, since it is an important regulator of vascular nitric oxide production 6. Using our algorithms to analyse the nocturnal TcCO2 plateaus and sudden TcCO2 descents, we have previously been able to predict nitric oxide mediated vasodilatation in pre-menopausal females 7 and metabolic status in patients with suspected sleep apnoea 8.

In females, the risk of metabolic syndrome (defined as insulin resistance, abdominal obesity, dyslipidemia and elevated blood pressure), increases during the menopausal transition 9, 10. The early detection of developing metabolic abnormalities in this population would be key to preventing or reducing the effects of metabolic syndrome and its complications. Therefore, we performed sleep studies, including all-night TcCO2 recordings, in a so far healthy population of post-menopausal females with two specific aims. First, we wanted to evaluate further the performance of our TcCO2 analysis in predicting metabolic variables such as glycosylated haemoglobin A1C (GHbA1C), blood pressure (BP), and plasma lipoprotein cholesterols and triglycerides in a group of individuals whose pre-test probability of metabolic syndrome was lower than that of the patients with suspected sleep apnoea in our previous study. Our second aim was to screen a number of nocturnal TcCO2 features, along with other sleep parameters, for their potential to predict metabolic abnormalities and increased cardiovascular risk in these subjects.

METHODS

Subjects

22 healthy post-menopausal females were recruited via a newspaper announcement advertising a sleep study. Subjects with a history of alcohol abuse, malignancies, diabetes, coronary heart disease, respiratory insufficiency or known SDB were excluded, as were subjects taking medication for hypercholesterolemia or hypertension. Five females with oestrogen therapy were allowed to continue with their medication, three used a transdermal gel, one a transdermal patch and one an oral preparation.

The study was approved by the Commission on Ethics of Turku University Central Hospital (Turku, Finland). Written informed consent was obtained from all subjects.

Subject characteristics, blood tests and questionnaires

The neck, waist and hip circumferences, body mass index (BMI), evening resting BP and forced expiratory volume in 1 s (FEV1) were measured as described previously 11. Venous blood samples for the assessment of plasma total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides (Modular Analytics P-analyzer®; Roche/Hitachi, Tokyo, Japan), GHbA1C (Variant II®; Bio-RAD Laboratories Diagnostics Group, Hercules, CA, USA) and follicle stimulating hormone (FSH) (AutoDelfia®; Wallac, Turku) were collected on the morning prior to the sleep study, following an overnight fast. LDL cholesterol was calculated using Friedewald's formula. A personal medical history, including smoking habits and medications, was collected using structured questionnaires in the presence of an investigator or study nurse.

Overnight measurements

Sleep recordings involved the overnight monitoring of the electroencephalogram (C3/A2, C4/A1, O1/A2, O2/A1), electro-oculogram and the mandibular electromyogram (Embla®; Medcare Flaga hf. Medical Devices, Reykjavik, Iceland). Nasal air flow was measured with nasal prongs attached to a pressure sensor of the Embla®/Somnologica system (Medcare Flaga hf. Medical Devices). The arterial oxygen saturation (Sa,O2) was measured by two finger-probe pulse oximeters (Nonin® oximeter built into the Embla®/Somnologica system and the Ohmeda Biox 3700 Pulse Oximeter® (Biomed Technologies Inc., Stoughton, MA, USA; recorded using the Uniplot® software, Unesta, Turku)). TcCO2 was measured using a TCM3 device (Radiometer®; Copenhagen, Denmark) 12. After cleansing the skin with alcohol, the skin sensor was placed on the upper part of the chest parasternally and heated to 43°C, at which temperature the sensor remained attached during the night for ∼8 h 13. Before each recording, the TcCO2 signal was calibrated by flushing the sensor with a calibration gas containing a 5% concentration of CO2.

The time that the subjects spent in bed was not strictly limited. Subjects went to bed around their usual bedtime and were woken up at around 07.30 h if they had not already woken up earlier. Sleep stages, including stage 1, stage 2, combined slow-wave sleep (SWS; stages 3 and 4) and rapid eye movement (REM) sleep, were visually scored in 30-s epochs according to the criteria of Rechtschaffen and Kales 14. Sleep onset was determined by the appearance of the first 30 s of sleep. The time before sleep onset was defined as evening wakefulness. The end of the sleep period was determined by the final arousal leading to wakefulness. Sleep latency was defined as the period from the beginning of the recording to sleep onset. Sleep efficiency was expressed as the percentage of total sleep time in the sleep period. Arousals were defined using the American Sleep Disorders Association definition 15.

The Sa,O2 signal was recorded with a sampling frequency of 1 Hz and TcCO2 with a sampling frequency of 100 Hz throughout the night using the Embla® system. Episodes of arterial oxyhaemoglobin desaturation of 3% and 4% units or more per hour (ODI3 and ODI4) were calculated using the Embla/Somnologica® or the Uniplot® software. The apnoea/hypopnoea index (AHI) was visually determined using the Embla/Somnologica® software and the American Academy of Sleep Medicine criteria 16. An episode of apnoea was defined as a cessation of airflow for ≥10 s. Hypopnoea was defined as a marked reduction in the nasal flow signal lasting for ≥10 s that was associated with a reduction in the oxyhaemoglobin saturation from the pre-event baseline of at least 4%.

Processing of the TcCO2 signal

Details of the TcCO2 signal processing are provided in the supplementary data, and are only described briefly herein. First, obvious artefacts at the beginning or at the end of the TcCO2 recordings were manually removed. The artefacts in the middle of the recordings were replaced with constant line segments. The median overnight TcCO2 levels were calculated for each sleep stage (S1, S2, SWS, REM sleep and wakefulness), as well as the percentage of time the signal stayed above 7 kPa. Special attention was paid to abrupt TcCO2 descents, referred to as pit patterns. Each pit pattern was characterised by its descent (amplitude, duration and slope). The highest TcCO2 plateau (maximal plateau) was defined visually from each curve. An example of a TcCO2 curve with a pit pattern and maximal plateau is shown in figure 1⇓.

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

Representative overnight recording of the transcutaneous carbon dioxide (TcCO2) as function of sleep stages and events. Episodes of TcCO2 pit patterns, apnoea, hypopnoea, desaturation and arousals per hour are illustrated below the hypnogram. The TcCO2 signal insert corresponds to a single pit pattern. The pit patterns were analysed for amplitude, duration and slope. The TcCO2 level during evening wakefulness and the maximal TcCO2 plateau are indicated. - - - -: the 7 kPa threshold. Other features extracted from the TcCO2 signal include median TcCO2 levels in the various sleep stages. REM: rapid eye movement.

Regression analyses

Standard multiple linear regression analyses with stepwise feature selection were carried out individually for each metabolic variable (GHbA1C, HDL and LDL cholesterol and triglycerides, and blood pressure). Predictors included the overnight TcCO2 and Sa,O2 features, as well as the sleep architecture measures. The neck and waist circumferences, waist-to-hip ratio, BMI and FSH were used as confounding factors in the prediction models. At each step, the most significant feature not yet in the regression model was entered, provided that its individual significance was sufficient (p<0.05), and the insignificant (p>0.10) features were removed. The standard F-test was used to assess the significance of each feature in terms if its contribution to the R2 change. The feature selection algorithm was terminated as soon as no more features could be included or removed. Multicollinearity was tested by computing the variance inflation factor (VIF) for each model variable. VIF factors for the model variables were <2 (1.023 and 1.011), which indicates that possible collinearity of the model variables was not a concern. The difference in the frequency of pit patterns (pit index) between non-REM (NREM) and REM sleep was assessed with paired t-tests. The statistical analyses were performed with the default values in the SPSS 12 software (SPSS Inc., Chicago, IL, USA).

RESULTS

Each of the 22 females participated in the overnight measurements (fig. 1⇑). The demographic data of the study group is presented in table 1⇓. The females were mildly overweight (mean BMI 25.3 kg·m−2). Two of the females had a BMI >30 kg·m−2. Seven females had a systolic BP (SBP) >140 mmHg and six females had a diastolic BP (DBP) >90 mmHg. One subject had a GHbA1C of 6.1 %, and 17 subjects had total cholesterol >5 mmol·L−1. The inter-relationships between the metabolic variables used in the linear regression models are presented in table 2⇓. The FEV1 ranged from 77% to 146% of predicted values and the median FEV1 was 95%. In all of the females, FSH was in the post-menopausal levels ranging from 31 to 140 IU·L−1. The subjects included four habitual smokers, two occasional smokers and four habitual snorers (snored at least three nights per week). None of the subjects had chronic obstructive pulmonary disease or asthma. Two females regularly used acetylsalicylic acid, one used cetirizine for allergic symptoms and gastric mucoprotective drugs and one female was on citalopram.

View this table:
  • View inline
  • View popup
Table 1—

Subject characteristics and metabolic measurements

View this table:
  • View inline
  • View popup
Table 2—

Pairwise inter-relationships between metabolic variables

The mean±sd values of the sleep architecture measures from the sleep study are shown in table 3⇓. The Sa,O2 and TcCO2 measurements are presented in table 4⇓. None of the subjects had an ODI4 of >5 events·h−1. Two subjects had an AHI of >5 events·h−1 (7 and 8 events·h−1, respectively). The nocturnal frequency of pit patterns was computed individually for both REM and NREM sleep states, with the pit index being considerably higher in REM sleep (p<0.001). In the final multivariate results, age was not taken as a predictor because it did not show a significant correlation with any of the metabolic variables (correlations ranged from 0.233 to 0.303 and the p-values from 0.171 to 0.947).

View this table:
  • View inline
  • View popup
Table 3—

Sleep architecture measures

View this table:
  • View inline
  • View popup
Table 4—

Overnight transcutaneous carbon dioxide(TcCO2) and arterial oxygen saturation (Sa,O2) measurements

Nocturnal measurements as predictors of metabolic variables

The features selected using the stepwise multiple linear regression analyses supported the importance of the novel TcCO2 features in predicting metabolic variables (table 5⇓). In contrast, none of the Sa,O2 or demographic features were selected as predictors of the metabolic variables. In addition, AHI, ODI3 and ODI4 were insignificant predictors. As well as the nocturnal TcCO2 features, a longer sleep period was found to be an important predictor of lower GHbA1C, and increased sleep fragmentation of lower HDL cholesterol. High levels of TcCO2 (percentage of time over 7 kPa) were linked with lower GHbA1C and triglycerides. The maximal plateau of the TcCO2 curve associated positively with the HDL/total cholesterol ratio. In addition, high evening levels of TcCO2 were linked with a lower evening SBP. Furthermore, a high nocturnal frequency of pit patterns predicted lower HDL cholesterol. The slope of the pit patterns was related both with low total cholesterol and low LDL cholesterol. Moreover, higher amplitude of the pit pattern was associated with lower DBP.

View this table:
  • View inline
  • View popup
Table 5—

Stepwise linear regression analysis with overnight measurements as predictors of metabolic variables

DISCUSSION

In our study population of generally healthy 55-yr-old post-menopausal females, nocturnal TcCO2 features were the most important predictors of GHbA1C, BP and cholesterol levels (table 5⇑). A longer sleep period was linked with a lower GHbA1C, and fragmented sleep with lower HDL cholesterol, as suggested by previous studies 17, 18. Mean and nadir Sa,O2, ODI4, AHI, BMI values and waist circumference were worse predictors of metabolic variables in this population. Subjects were all generally healthy, although marginally overweight, and with BP and waist circumference slightly exceeding the International Diabetes Federation reference values 19 (table 1⇑). Despite this, the overnight TcCO2 features were systematically associated with the metabolic variables. Our results provide further support to our earlier findings that, irrespective of the study population, the nocturnal TcCO2 profile contains risk factor information on metabolic diseases 8. It is possible that increasing TcCO2 levels during sleep indicate decent vasodilatation capacity in the silence of sympathetic drive, whereas sudden TcCO2 decreases (pit patterns) indicate surges of sympathetic activity that cause exaggerated vasoconstrictive responses when endothelial dysfunction is present. The feasibility of interaction between the local CO2 events and endothelial dysfunction is further strengthened by the observation that the CO2 mediated autoregulatory vasodilatation is mediated through nitric oxide 6. The nocturnal TcCO2 features have a high predictive power on daytime endothelial function tests 7, suggesting that local CO2 is a major controller of local nitric oxide production. Further studies are needed to establish to what extent nocturnal TcCO2 events display local nitric oxide production.

Menopause increases the risk of SDB 20, 21, which in turn is also known to be a risk factor for metabolic syndrome and cardiovascular disorders 2, 22. Our study population was a group of clinically healthy females with age and post-menopausal status as risk factors, which gave us a unique setting to search for signs of emerging metabolic syndrome. CO2, which is the final metabolic end product, played a major role in our results. A TcCO2 sensor measures the CO2 that diffuses through the skin, and its measurements are affected by central respiratory drive, peripheral vascular perfusion and local tissue metabolism 12, 23. Conventional severity indexes of sleep apnoea (AHI, ODI3, ODI4 or Sa,O2) were not found to be important in this population with relatively little SDB. This suggests that the TcCO2 features predict metabolic variables independently of hypoxaemia or SDB.

The high overnight levels of TcCO2 were one of the new key predictors for protective metabolic variables in our earlier study in patients with sleep apnoea 8. This association was also found in the present study, despite an essentially different study population (healthy post-menopausal females). The longer the subjects maintained their TcCO2 at >7 kPa, the lower their levels of GHbA1C and triglycerides. Furthermore, the visually detected maximal plateau of the TcCO2 curve associated positively with the HDL/total cholesterol ratio. These results are encouraging, yet they should be interpreted with caution, since we have no explicit data about “the normal” TcCO2 ranges during sleep. It is probable that nocturnal TcCO2 variables differ between sexes and change with increasing age, after the menopause 11 or during oestrogen therapy 24. However, the findings are in line with the earlier TcCO2 profile results and, in particular, with the results from our previous work that the proportion of high TcCO2 levels measured during sleep were one of the most important features for classifying insulin resistance 8.

Obstructive sleep apnoea (OSA) and snoring are associated with insulin resistance and an impaired lipid profile 3, 25, 26. OSA may decrease the arterial CO2 tension due to repetitive arousals and hyperventilation following each apnoea. Therefore, it is possible that people with even mild sleep disturbances cannot achieve as high TcCO2 levels as coeval healthy people because episodes of apnoea, snoring or frequent arousals interrupt sleep. This is in line with the finding that awakening is usually followed by a notable descent in the TcCO2 tension (fig. 1⇑), while falling asleep is typically related to a rise in TcCO2 11.

In the present study, we classified the TcCO2 features according to the sleep stages and found that TcCO2 pit patterns occur significantly more often in REM sleep and wakefulness than in other sleep stages (fig. 1⇑). Normally sympathetic activity dominates during wakefulness and appears as bursts during REM sleep. NREM sleep is characterised by parasympathetic dominance. Sympathovagal imbalance is common in metabolic syndrome, but its definitive causative role has not been demonstrated 27. Pit patterns may result from sudden bursts of sympathetic activity that produce peripheral vasoconstriction. These bursts may appear more consistently during sympathetic dominance. Subjects with a high pit index had a lower HDL cholesterol concentration, confirming our previous findings 8. Low HDL cholesterol has previously been linked with a greater frequency of arousals 17. Likewise, in our study, sleep fragmentation was the other predictor of HDL cholesterol. As arousals and awakenings increase sympathetic activation during sleep, it is possible that they also produce the pit patterns. Spiegel et al. 28 have shown that glucose metabolism is impaired with increased sympathetic tone, which has been induced by partial short-term sleep deprivation. If TcCO2 reflects sympathovagal balance, then during parasympathetic dominance when periferic blood vessels are dilated, TcCO2 levels are high.

Another feature of the TcCO2 patterns is the amplitude and sharpness of the pits. The fast and deep descents appear to be associated with low LDL and total cholesterol levels. In addition, high amplitude of pit pattern was the only predictor of low DBP. This further supports the idea of TcCO2 as a reflector of sympathovagal balance. By monitoring the transient TcCO2 events against the prevailing parasympathetic tone, the bursts of sympathetic nervous activity can be distinguished more clearly. The dominance of sympathetic activity may diminish the amplitudes of the pit patterns.

The only predictor for SBP was the evening wakefulness level of TcCO2. As CO2 is a known vasodilatator 29, this may explain why subjects with a high TcCO2 had a lower SBP. The possible protective effect of higher TcCO2 is also in line with the findings in females with SDB. Those with a predominantly partial upper airway obstruction during sleep (flow limitation) combined with increased TcCO2 levels had less hypertension than in patients with OSA 30. However, high TcCO2 did not associate with DBP. Anderson et al. 31 have previously demonstrated that high end-tidal CO2 predicts high SBP in females. End-tidal CO2 measures the CO2 concentration in the alveoli and is strongly affected by changes in ventilation, whereas TcCO2 is also affected by tissue metabolism and local vasodynamics. Hence, end-tidal CO2 and TcCO2 are likely to measure different phenomena. However, the results of Anderson et al. 31 show that breathing is an important contributor in the development of hypertension. The BP of OSA patients is higher than in healthy controls 32 and nocturnal hypoxia elevates BP 33. Generally, poor sleep seems to be an important risk factor for hypertension because sleep fragmentation, arousals and short self-reported sleep duration are associated with high blood pressure 17, 34, 35. These variables did not predict BP in our study. This may be due to the relatively small and healthy study population.

The risk of metabolic syndrome increases around the time of menopause 9, 10, 36. Therefore, one would expect to find some variation in our study population, even if all of the females were generally healthy. Central obesity is a known risk factor for insulin resistance 37. However, in our study, it did not turn out to be an important contributor, probably because most of our subjects were rather lean (table 1⇑). Neither the duration nor the proportion of SWS turned out to be important predictors in our study population, even though van Tasali et al. 1 recently showed that a short SWS duration is associated with an increased risk of diabetes. This may be because of our healthy sample, as only one female had a GHbA1C >6%. In addition to the SWS duration, self-reported short sleep has been linked with obesity and diabetes 18, 38. These studies are in line with our results, that a long sleep period (assuming that the length of a subject's sleep period in a sleep laboratory reflects their normal sleep period) was the most important predictor of lower GHbA1C. In addition, sleep fragmentation was a predictor of decreased HDL cholesterol. Recently, Ekstedt et al. 17 showed that the number of arousals predicted lower HDL cholesterol. Together, these results suggest the importance of adequate length and quality of sleep in the prevention of metabolic disorders. Short and fragmented sleep may disturb the TcCO2 signal, which seems to be sensitive to subtle nocturnal changes. This may explain why in our results the TcCO2 features play such an important role. However, more studies are still needed to confirm the results.

Our study has some potential confounders and limitations. The cross-sectional study design does not allow us to confirm whether CO2 plays a causative role, or whether the TcCO2 profile is a marker of some other underlying pathophysiological process. Moreover, the number of subjects was relatively small and heterogeneous in terms of hormone replacement therapy. Although the subjects were all around the same age, the time from menopause varied (table 1⇑). The time from menopause was not included in linear regression models as only 13 (59%) females remembered their exact time of menopause. This, together with the cross-sectional study design, makes it impossible to separate the influence of age and menopause. In addition, oestrogen deficiency affects metabolism 10. Oestrogen usage was not selected as an exclusion criterion because our main goal was not to study the effects of oestrogen but to find the predictors for a wide range of metabolic variables. Moreover, grouping the subjects based on the oestrogen usage did not reveal differences in any of the measurements (unpaired t-test p>0.1). Some potential pitfalls in the subject selection could be criticised as well. The subjects were recruited through newspaper announcements, calling healthy post-menopausal females for a sleep and cardiovascular study. Some members of this group of “healthy” subjects may have been compelled to participate in such a study due to subclinical hidden sleep problems or cardiovascular family risk factors. However, none of the subjects regularly used hypnotic drugs.

Conclusions

Nocturnal TcCO2 features can predict metabolic variables including GHbA1C, HDL and LDL cholesterol, triglycerides and BP in healthy post-menopausal females. Conventional measures such as waist circumference and nocturnal hypoxia were not important predictors in our study population. Monitoring TcCO2 events (the pit patterns) against the prevailing parasympathetic tone (TcCO2 plateaus) during sleep may reveal abnormal endothelium responses to the activation of the sympathetic nervous system, which may result from abnormal metabolic processes. These results may have important medical implications, ranging from an understanding of the potential mechanisms underlying the disease pathogenesis to improved diagnostic methods for assessing the risk of developing metabolic syndrome.

Support statement

This work was supported by grants from the Finnish Anti-Tuberculosis Association Foundation, Tampere Tuberculosis Foundation, Aarne and Aili Turunen Foundation, Väinö and Laina Kivi Foundation, Academy of Finland, Paulo Foundation, the Jalmari and Rauha Ahokas Foundation, Orion-Farmos Research Foundation, the Research Foundation for Respiratory Diseases and the governmental EVO-grant of the Turku University Hospital (All Finland).

Statement of interest

None declared.

Footnotes

  • This article has supplementary data which is accessible from www.erj.ersjournals.com

  • Received February 2, 2009.
  • Accepted June 6, 2009.
  • © ERS Journals Ltd

References

  1. ↵
    Tasali E, Leproult R, Ehrmann DA, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 2008;105:1044–1049.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005;9:211–224.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Williams CJ, Hu FB, Patel SR, et al. Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care 2007;30:1233–1240.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Clark JS, Votteri B, Ariagno RL, et al. Noninvasive assessment of blood gases. Am Rev Respir Dis 1992;145:220–232.
    OpenUrlPubMedWeb of Science
  5. ↵
    Healey CJ, Fedullo AJ, Swinburne AJ, et al. Comparison of noninvasive measurements of carbon dioxide tension during withdrawal from mechanical ventilation. Crit Care Med 1987;15:764–768.
    OpenUrlPubMedWeb of Science
  6. ↵
    Lavi S, Gaitini D, Milloul V, et al. Impaired cerebral CO2 vasoreactivity: association with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2006;291:H1856–H1861.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Aittokallio J, Polo O, Hiissa J, et al. Overnight variability in transcutaneous carbon dioxide predicts vascular impairment in women. Exp Physiol 2008;93:880–891.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Virkki A, Polo O, Saaresranta T, et al. Overnight features of transcutaneous carbon dioxide measurement as predictors of metabolic status. Artif Intell Med 2008;42:55–65.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Davidson MH, Maki KC, Karp SK, et al. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 2002;19:169–178.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538–554.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Aittokallio J, Virkki A, Aittokallio T, et al. Non-invasive respiratory monitoring during wakefulness and sleep in pre- and postmenopausal women. Respir Physiol Neurobiol 2006;150:66–74.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Baumbach P. Understanding Transcutaneous pO2 and pCO2 Measurements. Radiometer Medical A/S, Denmark, 1997
  13. ↵
    Janssens JP, Perrin E, Bennani I, et al. Is continuous transcutaneous monitoring of PCO2 (TcPCO2) over 8 h reliable in adults? Respir Med 2001;95:331–335.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring Systems for Sleep Stages of Human Subjects. National Institutes of Health, Washington, 1968
  15. ↵
    EEG arousals: scoring rules and examples. A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173–184.
    OpenUrlPubMed
  16. ↵
    Iber C, Ancoli-Israel S, Chesson A, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specification. 1st Edn. American Academy of Sleep Medicine, Westchester, IL, 2007
  17. ↵
    Ekstedt M, Åkerstedt T, Söderström M. Microarousals during sleep are associated with increased levels of lipids, cortisol, and blood pressure. Psychosom Med 2004;66:925–931.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007;30:1667–1673.
    OpenUrlPubMedWeb of Science
  19. ↵
    Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–1062.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001;163:608–613.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2003;167:1181–1185.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Hamilton GS, Solin P, Naughton MT. Obstructive sleep apnoea and cardiovascular disease. Intern Med J 2004;34:420–426.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Lubbers DW. Theoretical basis of the transcutaneous blood gas measurements. Crit Care Med 1981;9:721–733.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Aittokallio J, Hiissa J, Saaresranta T, et al. Nocturnal transcutaneous carbon dioxide tension in postmenopausal estrogen-users and non-users. Menopause Int 2009;15:107–112.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Borgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006;27:121–127.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670–676.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Frontoni S, Bracaglia D, Gigli F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr Metab Cardiovasc Dis 2005;15:441–449.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999;354:1435–1439.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Atkinson JL, Anderson RE, Sundt TM Jr. The effect of carbon dioxide on the diameter of brain capillaries. Brain Res 1990;517:333–340.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Anttalainen U, Polo O, Vahlberg T, et al. Reimbursed drugs in patients with sleep-disordered breathing: a static-charge-sensitive bed study. Sleep Med 2009; [Epub ahead of print PMID: 19620024]
  31. ↵
    Anderson DE, Parsons DJ, Scuteri A. End tidal CO2 is an independent determinant of systolic blood pressure in women. J Hypertens 1999;17:1073–1080.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Hla KM, Young TB, Bidwell T, et al. Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994;120:382–388.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Arabi Y, Morgan BJ, Goodman B, et al. Daytime blood pressure elevation after nocturnal hypoxia. J Appl Physiol 1999;87:689–698.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first national health and nutrition examination survey. Hypertension 2006;47:833–839.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Morrell MJ, Finn L, Kim H, et al. Sleep fragmentation, awake blood pressure, and sleep-disordered breathing in a population-based study. Am J Respir Crit Care Med 2000;162:2091–2096.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918–923.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin Dermatol 2004;22:289–295.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Gangwisch JE, Malaspina D, Boden-Albala B, et al. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep 2005;28:1289–1296.
    OpenUrlPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 34 Issue 5 Table of Contents
European Respiratory Journal: 34 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Transcutaneous carbon dioxide profile during sleep reveals metabolic risk factors in post-menopausal females
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Transcutaneous carbon dioxide profile during sleep reveals metabolic risk factors in post-menopausal females
J. Aittokallio, T. Saaresranta, A. Virkki, N. Karppinen, O. J. Heinonen, T. Aittokallio, O. Polo
European Respiratory Journal Nov 2009, 34 (5) 1132-1139; DOI: 10.1183/09031936.00017909

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Transcutaneous carbon dioxide profile during sleep reveals metabolic risk factors in post-menopausal females
J. Aittokallio, T. Saaresranta, A. Virkki, N. Karppinen, O. J. Heinonen, T. Aittokallio, O. Polo
European Respiratory Journal Nov 2009, 34 (5) 1132-1139; DOI: 10.1183/09031936.00017909
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Support statement
    • Statement of interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Optimal positive airway pressure predicts oral appliance response to sleep apnoea
  • Nasopharyngoscopic evaluation of oral appliance therapy for obstructive sleep apnoea
  • Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea
Show more Original Articles: Sleep-related disorders

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society